BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 25544648)

  • 1. Dosimetric analysis of urethral strictures following HDR (192)Ir brachytherapy as monotherapy for intermediate- and high-risk prostate cancer.
    Díez P; Mullassery V; Dankulchai P; Ostler P; Hughes R; Alonzi R; Lowe G; Hoskin PJ
    Radiother Oncol; 2014 Dec; 113(3):410-3. PubMed ID: 25544648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot study on dosimetric and radiomics analysis of urethral strictures following HDR brachytherapy as monotherapy for localized prostate cancer.
    Tsang YM; Vignarajah D; Mcwilliam A; Tharmalingam H; Lowe G; Choudhury A; Hoskin P
    Br J Radiol; 2020 Feb; 93(1106):20190760. PubMed ID: 31778319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The dosimetry of prostate brachytherapy-induced urethral strictures.
    Merrick GS; Butler WM; Tollenaar BG; Galbreath RW; Lief JH
    Int J Radiat Oncol Biol Phys; 2002 Feb; 52(2):461-8. PubMed ID: 11872293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between prostate brachytherapy-related urethral stricture and peri-apical urethral dosimetry: a matched case-control study.
    Earley JJ; Abdelbaky AM; Cunningham MJ; Chadwick E; Langley SE; Laing RW
    Radiother Oncol; 2012 Aug; 104(2):187-91. PubMed ID: 22841018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urethral stricture following high dose rate brachytherapy for prostate cancer.
    Sullivan L; Williams SG; Tai KH; Foroudi F; Cleeve L; Duchesne GM
    Radiother Oncol; 2009 May; 91(2):232-6. PubMed ID: 19097660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for urethral stricture following external beam radiotherapy and HDR brachytherapy for prostate cancer.
    Groom N; Tsang Y; Lowe G; Hoskin P
    Brachytherapy; 2021; 20(2):302-306. PubMed ID: 33234408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for the development of prostate brachytherapy related urethral strictures.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Anderson RL; Allen ZA; Adamovich E
    J Urol; 2006 Apr; 175(4):1376-80; discussion 1381. PubMed ID: 16516001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry.
    Neill M; Studer G; Le L; McLean M; Yeung I; Pond G; Crook JM
    Brachytherapy; 2007; 6(3):173-9. PubMed ID: 17681239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel urethral sparing technique for high-dose-rate prostate brachytherapy after transurethral resection of the prostate.
    Kunogi H; Cunha JAM; Chang AJ; Gadzinski AJ; Shinohara K; Hsu IC
    Brachytherapy; 2017; 16(6):1113-1118. PubMed ID: 28869143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with Hypofractionated External beam radiotherapy for localized prostate cancer: an analysis to determine the correlation between dose-volume histogram parameters in HDR brachytherapy and severity of toxicity.
    Ishiyama H; Kitano M; Satoh T; Kotani S; Uemae M; Matsumoto K; Okusa H; Tabata K; Baba S; Hayakawa K
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):23-8. PubMed ID: 19243900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interstitial rotating shield brachytherapy for prostate cancer.
    Adams QE; Xu J; Breitbach EK; Li X; Enger SA; Rockey WR; Kim Y; Wu X; Flynn RT
    Med Phys; 2014 May; 41(5):051703. PubMed ID: 24784369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxicity and early treatment outcomes in low- and intermediate-risk prostate cancer managed by high-dose-rate brachytherapy as a monotherapy.
    Ghadjar P; Keller T; Rentsch CA; Isaak B; Behrensmeier F; Stroux A; Thalmann GN; Aebersold DM
    Brachytherapy; 2009; 8(1):45-51. PubMed ID: 19038584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urethral and bladder dosimetry of total and focal salvage Iodine-125 prostate brachytherapy: Late toxicity and dose constraints.
    Peters M; van der Voort van Zyp J; Hoekstra C; Westendorp H; van de Pol S; Moerland M; Maenhout M; Kattevilder R; van Vulpen M
    Radiother Oncol; 2015 Nov; 117(2):262-9. PubMed ID: 26349590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between the dose to the bulbomembranous urethra and stricture after high dose-rate brachytherapy for prostate cancer: Matched-pair analysis.
    Sekiguchi A; Tsumura H; Kawakami S; Satoh T; Iwamura M; Ishiyama H
    Int J Urol; 2019 Sep; 26(9):938-939. PubMed ID: 31256422
    [No Abstract]   [Full Text] [Related]  

  • 17. Segmental urethral dosimetry and urinary toxicity in patients with no urinary symptoms before permanent prostate brachytherapy.
    Thomas C; Keyes M; Liu M; Moravan V
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):447-55. PubMed ID: 18395357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity.
    Allen ZA; Merrick GS; Butler WM; Wallner KE; Kurko B; Anderson RL; Murray BC; Galbreath RW
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):981-7. PubMed ID: 15989998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct 2-arm comparison shows benefit of high-dose-rate brachytherapy boost vs external beam radiation therapy alone for prostate cancer.
    Khor R; Duchesne G; Tai KH; Foroudi F; Chander S; Van Dyk S; Garth M; Williams S
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):679-85. PubMed ID: 22954770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A surrogate urethra for real-time planning of high-dose-rate prostate brachytherapy.
    Halperin H; Hilts M; Crook J; Batchelar D; Tisseverasinghe S; Tetreault-LaFlamme A; Bachand F
    Brachytherapy; 2019; 18(5):675-682. PubMed ID: 31248822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.